What research says about nightmare treatment

Start with the difficulty you want help with

A useful starting question is not “Which symbol must be removed?” but “What is making sleep or daily life difficult?” You might want to describe repeated awakenings, distress afterwards, reluctance to go to bed, or an effect on the following day. This is an optional way to communicate a concern, not a self-diagnosis checklist.

An occasional unpleasant story and a persistent difficulty need not lead to the same conversation. You also do not have to settle on a diagnosis before describing what is happening. The purpose of an appointment can be to clarify that very question, including whether the remembered dreams are the main problem or one part of a wider sleep difficulty.

A trial asks a narrower question than a promise

Read the sources as three different evidence questions.

The 2018 AASM position addresses adult nightmare disorder and PTSD-associated nightmares. Its recommendation is a professional position about treatment, not the result of a single comparison.

The 2023 VA/DoD guideline addresses PTSD-associated nightmares. Its judgement of insufficient evidence for or against several approaches belongs to that specified population and evidence review.

The Kunze trial asks how two defined interventions compare with a waiting list in its recruited sample. The details and follow-up limits are set out below. A trial finding and a guideline judgement need not answer the same question.

For each, identify the population, outcome, comparison and date. Fewer nightmares, less distress and better overall sleep are distinct outcomes. The purpose is to read a claim accurately, not to make you score every dream or select treatment alone.

What the rescripting trial tested

Kunze and colleagues assigned 104 people with nightmare disorder to imagery rescripting, imaginal exposure or a waiting list. Both active groups reported lower nightmare frequency and distress than the waiting-list group. The abstract describes persistence of initial effects at three and six months; the sample predominantly had idiopathic nightmares.

A waiting list is a particular comparison. This trial does not establish that either approach is better than every other active treatment, or that findings apply identically to all trauma-related nightmares. The waiting-list group received treatment after four weeks; the later follow-up was not a continuing untreated-control comparison. It is evidence about a clinical intervention, not an instruction to undertake exposure without suitable support.

What the 2018 AASM position says

The American Academy of Sleep Medicine’s 2018 position-paper announcement recommends imagery rehearsal therapy for adult nightmare disorder and PTSD-associated nightmares. It distinguishes treatments that are recommended from those that may be used, with individual suitability left to clinical judgement.

Imagery-based approaches involve working with mental images in treatment. Naming a method here does not supply its assessment, adaptation or delivery. The important point for reading the recommendation is its date, adult population and stated outcome. It should not be presented as proof of complete agreement across every later guideline.

Names such as rehearsal, rescripting and exposure should not be treated as interchangeable just because a description mentions imagery. Check which intervention a source actually evaluated. This page compares the evidence and its scope; it does not provide an exposure exercise or a substitute for treatment planning.

Why PTSD guidance needs its own paragraph

The guideline authors’ 2024 synopsis of the 2023 VA/DoD PTSD guideline reports insufficient evidence for or against imagery rehearsal therapy and several related approaches for PTSD-associated nightmares. That conclusion concerns this specific population and outcome.

It is not a finding that the approaches can never help. Nor should it be silently replaced by the more affirmative AASM position. Readers deserve to see the difference. A clinician can explain which evidence and guideline applies to the person seeking care.

Medication evidence is outcome-specific

The same VA/DoD synopsis weakly suggests prazosin for PTSD-associated nightmares, while separately suggesting against its use for overall PTSD treatment. These recommendations address different outcomes.

That distinction does not instruct a reader to start, stop or change a medicine. Medication decisions belong in an individual clinical conversation, including other conditions and unwanted effects. A dream’s content cannot select a prescription.

Questions that keep an appointment useful

You might ask: “Which difficulty are we trying to improve?”; “What change would we monitor?”; “How does this evidence relate to my situation?”; or “What alternatives are available?” If a proposed exercise feels difficult to discuss, that itself can be part of the conversation. You need not provide a graphic account to this website.

These are communication prompts, not a treatment programme. There is no prescribed sequence, rehearsal timetable or requirement to confront a remembered scene here. The clinician and the person receiving care can agree what is appropriate, and how concerns about an approach will be addressed. A useful plan should make the next step clearer rather than make someone feel they must solve a dream correctly.

What improvement would and would not show

Suppose, as an invented example, someone receives care and later reports less distress on waking. That change concerns distress. It does not reveal a hidden meaning of the dream, prove that its characters represented particular people, or establish that every future night will be pleasant.

This distinction keeps the focus on the person’s goals. You can value better sleep without discovering why a particular image appeared. You can also report mixed progress: one difficulty improved and another remains. The nightmare guide provides a broader introduction; this article explains how to read the evidence behind treatment claims without turning it into a personalised prescription.

Sources & their limits

These sources support the statements indicated above. Their authors do not endorse this website or provide an assessment of your experience.

1. New position paper recommends treatment options for nightmare disorder in adults

   AASM position paper on adult nightmare treatments and recommendation strength.

   Cited in this guide · 3 places

   • A trial asks a narrower question than a promise
   • What the 2018 AASM position says
   • Do professional guidelines all make the same recommendation?
2. Efficacy of imagery rescripting and imaginal exposure for nightmares: A randomized wait-list controlled trial

   Randomized treatment comparison; primary methods and results checked, including the waiting-list crossover.

   Cited in this guide · 3 places

   • A trial asks a narrower question than a promise
   • What the rescripting trial tested
   • Did the randomised trial compare every available treatment?
3. The Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline

   Guideline authors’ synopsis of the 2023 VA/DoD recommendations for PTSD.

   Cited in this guide · 5 places

   • A trial asks a narrower question than a promise
   • Why PTSD guidance needs its own paragraph
   • Medication evidence is outcome-specific
   • Do professional guidelines all make the same recommendation?
   • Does insufficient evidence mean an approach never helps?

Put the context beside an experience

Continue through the science library